Redsense Medical AB (publ) (XSAT:REDS)
Sweden · Delayed Price · Currency is SEK 3.200
-0.030 (-0.93%)
At close: Aug 26, 2026
Redsense Medical AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 26.46 | 24.02 | 28.18 | 24.97 | 14.34 | 9.36 |
Other Revenue | - | - | - | - | 0 | - |
| 26.46 | 24.02 | 28.18 | 24.97 | 14.34 | 9.36 | |
Revenue Growth | -8.01% | -14.74% | 12.85% | 74.09% | 53.18% | -35.17% |
Cost of Revenue | 10.11 | 11.24 | 10.69 | 12.36 | 5.49 | 5.95 |
Gross Profit | 16.36 | 12.78 | 17.48 | 12.61 | 8.85 | 3.42 |
Selling, General & Admin | 18.4 | 18.66 | 19.76 | 17.54 | 22.46 | 22.77 |
Other Operating Expenses | -2.53 | -2.78 | -0.59 | 0.04 | -3.45 | -7.54 |
Operating Expenses | 17.17 | 16.5 | 19.24 | 17.64 | 19.06 | 15.41 |
Operating Income | -0.82 | -3.72 | -1.75 | -5.04 | -10.21 | -11.99 |
Interest Expense | -0.03 | -0.03 | -0.04 | -0.03 | -0.1 | -0.05 |
Interest & Investment Income | 0.31 | 0.23 | 0.17 | 0.06 | 1.02 | 1.05 |
Earnings From Equity Investments | - | - | - | - | - | -0.3 |
Currency Exchange Gain (Loss) | -0.11 | -3.65 | 1.96 | - | 2.5 | - |
Other Non Operating Income (Expenses) | 0 | - | - | - | -0 | 0 |
EBT Excluding Unusual Items | -0.65 | -7.17 | 0.34 | -5.01 | -6.79 | -11.29 |
Gain (Loss) on Sale of Investments | - | - | - | 0.5 | -1.97 | 3.32 |
Pretax Income | -0.65 | -7.17 | 0.34 | -4.51 | -8.76 | -7.97 |
Net Income | -0.65 | -7.17 | 0.34 | -4.51 | -8.76 | -7.97 |
Net Income to Common | -0.65 | -7.17 | 0.34 | -4.51 | -8.76 | -7.97 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 18 | 18 | 17 | 14 | 14 | 14 |
Shares Outstanding (Diluted) | 18 | 18 | 17 | 14 | 14 | 14 |
Shares Change | 3.00% | 4.85% | 21.25% | -0.16% | 0.60% | - |
EPS (Basic) | -0.04 | -0.40 | 0.02 | -0.32 | -0.62 | -0.57 |
EPS (Diluted) | -0.04 | -0.40 | 0.02 | -0.32 | -0.62 | -0.57 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -7.56 | -5.23 | -8.25 | -5.1 | -9.83 | -12.58 |
Free Cash Flow Per Share | -0.42 | -0.29 | -0.48 | -0.36 | -0.70 | -0.90 |
Gross Margin | 61.81% | 53.21% | 62.05% | 50.49% | 61.72% | 36.50% |
Operating Margin | -3.09% | -15.48% | -6.22% | -20.18% | -71.18% | -128.08% |
Profit Margin | -2.45% | -29.85% | 1.21% | -18.08% | -61.07% | -85.15% |
Free Cash Flow Margin | -28.57% | -21.77% | -29.27% | -20.44% | -68.55% | -134.38% |
EBITDA | -0.07 | -3.65 | -1.69 | -4.98 | -10.16 | -11.97 |
EBITDA Margin | -0.25% | -15.17% | -5.99% | -19.93% | -70.81% | -127.80% |
D&A For EBITDA | 0.75 | 0.07 | 0.07 | 0.06 | 0.05 | 0.03 |
EBIT | -0.82 | -3.72 | -1.75 | -5.04 | -10.21 | -11.99 |
EBIT Margin | -3.09% | -15.48% | -6.22% | -20.18% | -71.18% | -128.08% |
Revenue as Reported | 29.48 | 26.8 | 32.63 | 25.56 | 17.79 | 16.9 |